BioLeap, a developer of drug discovery technology, is sharing its molecule building technology in a research collaboration with Tokyo-based Kyorin Pharmaceuticals.
BioLeap’s technology takes a different approach to traditional drug development by making the process more flexible. It involves calculating how small branches of molecules will bind to a targeted protein, for example. Chemists use that information to assemble building blocks of new molecules.
The Pennington, New Jersey company’s software overcomes one of the biggest challenges in drug discovery — the limitations of patentable leads for biological targets, according to a press statement. It is designed to speed up drug discovery and reduce costs.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company was started in 2004 and raised $5 million in a series A financing round led by Quaker Partners and Adams Capital Management in 2010. It has signed collaborative agreements with companies such as GlaxoSmithKline (NYSE:GSK) and the Southern Research Institute, and with DuPont (NYSE:DD) and Syngenta (NYSE:SYT) for agricultural applications of its technology.